SCHEMBL4266746

SCHEMBL4266746

OCc1cc2ccnc(Cl)c2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 5/20 0.45
KDM5A P29375 3/20 0.45
KDM5B Q9UGL1 3/20 0.45
NUDT1 P36639 1/20 0.40
RECQL P46063 1/20 0.38
RHEB Q15382 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
DYRK1A Q13627 1/20 0.34
CBFB Q13951 1/20 0.34
KDM4A O75164 2/20 0.33
KRAS P01116 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CCNK O75909 1/20 0.32
CDK12 Q9NYV4 1/20 0.32
PLAU P00749 1/20 0.32
DAO P14920 1/20 0.32
CYP19A1 P11511 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13656919 0.79 RXFP1 (0.36) KDM4CKDM5AKDM5BRXFP1DYRK1A
Hydrochloric Acid SCHEMBL4269984 0.79 HRH1 (0.40) KDM4CKDM5AKDM5BRXFP1DYRK1A
Hydrochloric Acid SCHEMBL4276336 0.78 RXFP1 (0.35) KDM4CKDM5AKDM5BRXFP1DYRK1A
SCHEMBL13656918 0.76 RXFP1 (0.34) KDM4CKDM5AKDM5BRXFP1DYRK1A
Hydrochloric Acid SCHEMBL4267345 0.75 RXFP1 (0.33) KDM5AKDM5BRXFP1DYRK1ATDP1
SCHEMBL13656937 0.74 METAP2 (0.39)
SCHEMBL13656921 0.73 ROCK1 (0.45) KDM4CKDM5AKDM5BKDM4A
Hydrochloric Acid SCHEMBL4266912 0.73 METAP2 (0.38)
SCHEMBL2470176 0.73 RXFP1 (0.41) RXFP1DYRK1ATDP1DAOCYP19A1
SCHEMBL16795087 0.72 NUDT1 (0.46) KDM4CKDM5AKDM5BNUDT1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7608627-B2 I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-27 US disclosed
US-7608627-B2 I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-27 US disclosed
US-7608627-B2 I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-27 US disclosed
US-20080064715-A1 6-Azaindole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-13 US disclosed
US-20080064715-A1 6-Azaindole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-13 US disclosed
US-20080064715-A1 6-Azaindole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-13 US disclosed
EP-1732566-A2 6-AZAINDOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2006-12-20 EP disclosed
WO-2005097129-A2 6-AZAINDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064715-A1 6-Azaindole Compound RELA, NFKBIA, GPR119 KDM4C 940/4885KDM5A 778/4885KDM5B 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.